TP53 and carcinoma: The finding of TP53 mutations in non-dysplastic Barrett epithelia suggests that TP53 may be altered early in the metaplasia–dysplasia–carcinoma sequence, and it may therefore be a useful biomarker in endoscopic surveillance programs.